<DOC>
	<DOCNO>NCT02594254</DOCNO>
	<brief_summary>The purpose study evaluate C16G2 Gel administer certain period time either toothbrush custom dental tray effectively kill bacteria mouth cause dental cavity .</brief_summary>
	<brief_title>Phase 2 Study Evaluate Microbiology Safety C16G2 Administered Adult Adolescent Dental Subjects</brief_title>
	<detailed_description>This multi-center , multiple-arm study evaluate microbiological activity safety C16G2 Gel male female dental subject , 12 75 year age . The study conduct randomize , double-blind , placebo-controlled open-label manner enroll adolescent ( 12-17 year age ) adult subject ( 18-75 year age ) . A total approximately 128 study subject enrol 7 study arm . Study drug ( C16G2 Gel Placebo ) administer via manual brush gel application ( MBGA ) tray gel application ( TGA ) . Two C16G2 concentration evaluate . Four study arm conduct double blind manner , treatment allocation ratio 4:1 ( C16G2 : Placebo ) , three study arm conduct open-label manner . Before dose , eligible subject undergo professional dental prophylaxis Day 0 . Clinic visit study arm include Visit 1 ( Screening/Days -21 0 ) , vary number dose follow-up visit .</detailed_description>
	<mesh_term>Dental Caries</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<criteria>1 . Males female , 1275 year age , inclusive , time Assent and/or Informed Consent Form sign 2 . Female subject childbearing potential , define surgically sterile least two ( 2 ) year postmenopausal , must agree use one follow form contraception screen last study visit : hormonal ( oral , implant , injection ) begin &gt; 30 day prior screen ; barrier ( condom , diaphragm , cervical cap spermicide ) ; intrauterine device ( IUD ) . Acceptable contraceptive option may also include abstinence , relationship sex partner partner vasectomy least six ( 6 ) month prior screen visit 3 . Male subject : willing use contraception abstain sexual activity begin first exposure study drug continue discharge study due completion Early Termination 4 . Healthy , determine Investigator ( consultation Medical Monitor , need ) , base medical dental history , concurrent illness , laboratory result , concomitant medication , oral cavity assessment , target physical examination ( extraoral , head neck ) Screening Note : Subjects stable dose medication may eligible screen assessed Medical Monitor casebycase basis . 5 . Have minimum 12 bicuspid molar minimum 8 molar bicuspid NOT restoration , crown , sealant 6 . Demonstrated ability expectorate â‰¥2mL stimulate saliva 5 minute 7 . Have salivary S. mutans 1.0 x 105 CFUs/mL great Screening use MSB agar plat 8 . Willing refrain use nonstudy dentifrice nonstudy oral care product ( oral care rinse , fluoride product , etc . ) study 9 . Willing postpone elective dental procedure ( e.g. , dental cleaning ) Screening final posttreatment visit ( End Study Early Termination ) 10 . Willing able comply oral hygiene diet instruction 11 . Has dentition adequate custom dental tray gel application 12 . Able understand sign Assent and/or Informed Consent Form prior initiation study procedures 13 . Able communicate Investigator/study center personnel , understand comply study requirement , willing return protocolspecified visit appoint time 1 . Advanced periodontal disease 2 . Active caries lesion ( ) within 30 day prior study drug administration ( confirmed comprehensive caries examination include standard radiograph deem necessary Investigator ) Note : Subjects present insipient , noncavitated lesion ( ) exclude 3 . Medical condition ( e.g. , artificial heart valve , history infective endocarditis , cardiac transplant valvular dysfunction , congenital heart disease total joint replacement ) antibiotic recommend prior dental visit and/or procedure 4 . Pathologic lesion oral cavity ( suspicious confirm ) 5 . Full dentures orthodontic appliance , e.g. , brace ; Note : partial denture , removable retainer night guard exclude , provide clean regularly throughout duration study . 6 . Use systemic antibiotic , topical oral antibiotic , use drug , opinion Investigator could influence study outcome , within 30 day prior Screening throughout entire study . 7 . Medical history indicate woman pregnant , breastfeeding/lactating positive urine pregnancy test 8 . Participation clinical trial receipt nonFDA approve therapy within 30 day prior study drug administration ( depend specific , participation observational study necessarily exclude ) 9 . Prior participation C16G2 clinical trial know receive C16G2 active gel mouth rinse Note : Placebo subject exclude 10 . Presence condition concurrent illness , opinion Investigator , would compromise normal immune function ( e.g. , diabetes , rheumatoid arthritis , lupus , liver disease , organ transplant , etc . ) , interfere use study dentifrice oral care product , interfere ability comply study requirement , jeopardize safety subject validity study result</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>